Retina Consultants Houston   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Houston TX United States

Organization Overview

First Clinical Trial
2012
NCT01565148
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Retina Consultants Houston | Retinal Consultants of Houston

Active Ingredients

Drugs in Phase 4 Trials (2)

aflibercept (zaltrap) (4 trials)

ranibizumab (lucentis) (4 trials)

Drugs in Phase 2 Trials (1)

ico-007 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 2)

Edema (Phase 2)

Macular Degeneration (Phase 3)

Macular Edema (Phase 2)

Retinal Diseases (Phase 2)

Retinal Vein Occlusion (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 3